163 related articles for article (PubMed ID: 22335871)
1. Impact of multiparametric endorectal coil prostate magnetic resonance imaging on disease reclassification among active surveillance candidates: a prospective cohort study.
Margel D; Yap SA; Lawrentschuk N; Klotz L; Haider M; Hersey K; Finelli A; Zlotta A; Trachtenberg J; Fleshner N
J Urol; 2012 Apr; 187(4):1247-52. PubMed ID: 22335871
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of pre-biopsy multiparametric magnetic resonance imaging and clinical variables to reduce initial prostate biopsy in men with suspected clinically localized prostate cancer.
Numao N; Yoshida S; Komai Y; Ishii C; Kagawa M; Kijima T; Yokoyama M; Ishioka J; Matsuoka Y; Koga F; Saito K; Masuda H; Fujii Y; Kawakami S; Kihara K
J Urol; 2013 Aug; 190(2):502-8. PubMed ID: 23473904
[TBL] [Abstract][Full Text] [Related]
3. Multiparametric magnetic resonance imaging characterization of prostate lesions in the active surveillance population: incremental value of magnetic resonance imaging for prediction of disease reclassification.
Bonekamp D; Bonekamp S; Mullins JK; Epstein JI; Carter HB; Macura KJ
J Comput Assist Tomogr; 2013; 37(6):948-56. PubMed ID: 24270118
[TBL] [Abstract][Full Text] [Related]
4. Low-risk prostate cancer patients without visible tumor (T1c) on multiparametric MRI could qualify for active surveillance candidate even if they did not meet inclusion criteria of active surveillance protocol.
Lee DH; Koo KC; Lee SH; Rha KH; Choi YD; Hong SJ; Chung BH
Jpn J Clin Oncol; 2013 May; 43(5):553-8. PubMed ID: 23580758
[TBL] [Abstract][Full Text] [Related]
5. Magnetic Resonance Imaging Targeted Biopsy Improves Selection of Patients Considered for Active Surveillance for Clinically Low Risk Prostate Cancer Based on Systematic Biopsies.
Ouzzane A; Renard-Penna R; Marliere F; Mozer P; Olivier J; Barkatz J; Puech P; Villers A
J Urol; 2015 Aug; 194(2):350-6. PubMed ID: 25747105
[TBL] [Abstract][Full Text] [Related]
6. Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study.
Thompson JE; Moses D; Shnier R; Brenner P; Delprado W; Ponsky L; Pulbrook M; Böhm M; Haynes AM; Hayen A; Stricker PD
J Urol; 2014 Jul; 192(1):67-74. PubMed ID: 24518762
[TBL] [Abstract][Full Text] [Related]
7. Evaluating localized prostate cancer and identifying candidates for focal therapy.
Sartor AO; Hricak H; Wheeler TM; Coleman J; Penson DF; Carroll PR; Rubin MA; Scardino PT
Urology; 2008 Dec; 72(6 Suppl):S12-24. PubMed ID: 19095124
[TBL] [Abstract][Full Text] [Related]
8. Value of 3-T multiparametric magnetic resonance imaging and magnetic resonance-guided biopsy for early risk restratification in active surveillance of low-risk prostate cancer: a prospective multicenter cohort study.
Hoeks CM; Somford DM; van Oort IM; Vergunst H; Oddens JR; Smits GA; Roobol MJ; Bul M; Hambrock T; Witjes JA; Fütterer JJ; Hulsbergen-van de Kaa CA; Barentsz JO
Invest Radiol; 2014 Mar; 49(3):165-72. PubMed ID: 24220253
[TBL] [Abstract][Full Text] [Related]
9. Tumor lesion diameter on diffusion weighted magnetic resonance imaging could help predict insignificant prostate cancer in patients eligible for active surveillance: preliminary analysis.
Lee DH; Koo KC; Lee SH; Rha KH; Choi YD; Hong SJ; Chung BH
J Urol; 2013 Oct; 190(4):1213-7. PubMed ID: 23727188
[TBL] [Abstract][Full Text] [Related]
10. Prospective evaluation of endorectal magnetic resonance imaging to detect tumor foci in men with prior negative prostastic biopsy: a pilot study.
Perrotti M; Han KR; Epstein RE; Kennedy EC; Rabbani F; Badani K; Pantuck AJ; Weiss RE; Cummings KB
J Urol; 1999 Oct; 162(4):1314-7. PubMed ID: 10492187
[TBL] [Abstract][Full Text] [Related]
11. Magnetic resonance imaging on disease reclassification among active surveillance candidates with low-risk prostate cancer: a diagnostic meta-analysis.
Guo R; Cai L; Fan Y; Jin J; Zhou L; Zhang K
Prostate Cancer Prostatic Dis; 2015 Sep; 18(3):221-8. PubMed ID: 25986915
[TBL] [Abstract][Full Text] [Related]
12. Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer.
Welty CJ; Cowan JE; Nguyen H; Shinohara K; Perez N; Greene KL; Chan JM; Meng MV; Simko JP; Cooperberg MR; Carroll PR
J Urol; 2015 Mar; 193(3):807-11. PubMed ID: 25261803
[TBL] [Abstract][Full Text] [Related]
13. MRI and surveillance.
Ouzzane A; Puech P; Villers A
Curr Opin Urol; 2012 May; 22(3):231-6. PubMed ID: 22388665
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.
Krakowsky Y; Loblaw A; Klotz L
J Urol; 2010 Jul; 184(1):131-5. PubMed ID: 20478589
[TBL] [Abstract][Full Text] [Related]
15. Experience improves staging accuracy of endorectal magnetic resonance imaging in prostate cancer: what is the learning curve?
Latchamsetty KC; Borden LS; Porter CR; Lacrampe M; Vaughan M; Lin E; Conti N; Wright JL; Corman JM
Can J Urol; 2007 Feb; 14(1):3429-34. PubMed ID: 17324322
[TBL] [Abstract][Full Text] [Related]
16. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S
BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540
[TBL] [Abstract][Full Text] [Related]
17. Active surveillance for the management of prostate cancer in a contemporary cohort.
Dall'Era MA; Konety BR; Cowan JE; Shinohara K; Stauf F; Cooperberg MR; Meng MV; Kane CJ; Perez N; Master VA; Carroll PR
Cancer; 2008 Jun; 112(12):2664-70. PubMed ID: 18433013
[TBL] [Abstract][Full Text] [Related]
18. Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging.
Coakley FV; Chen I; Qayyum A; Westphalen AC; Carroll PR; Hricak H; Chen MH; Kurhanewicz J
BJU Int; 2007 Jan; 99(1):41-5. PubMed ID: 17227490
[TBL] [Abstract][Full Text] [Related]
19. Endorectal T2-weighted MRI does not differentiate between favorable and adverse pathologic features in men with prostate cancer who would qualify for active surveillance.
Guzzo TJ; Resnick MJ; Canter DJ; Bivalacqua TJ; Rosen MA; Bergey MR; Magerfleisch L; Tomazewski JE; Wein AJ; Malkowicz SB
Urol Oncol; 2012; 30(3):301-5. PubMed ID: 21856187
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonance imaging.
Liauw SL; Pitroda SP; Eggener SE; Stadler WM; Pelizzari CA; Vannier MW; Oto A
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):378-84. PubMed ID: 22717242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
